The Manufacturers Life Insurance Company Has $8.97 Million Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

The Manufacturers Life Insurance Company lowered its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 6.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 100,311 shares of the medical equipment provider's stock after selling 7,441 shares during the period. The Manufacturers Life Insurance Company owned about 0.14% of Lantheus worth $8,974,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in LNTH. State of New Jersey Common Pension Fund D increased its holdings in Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock worth $2,364,000 after purchasing an additional 115 shares in the last quarter. Bleakley Financial Group LLC boosted its stake in shares of Lantheus by 6.1% during the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock worth $200,000 after buying an additional 129 shares during the last quarter. Avantax Advisory Services Inc. boosted its stake in shares of Lantheus by 5.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after buying an additional 132 shares during the last quarter. Foundry Partners LLC boosted its stake in shares of Lantheus by 4.5% during the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock worth $278,000 after buying an additional 133 shares during the last quarter. Finally, UMB Bank n.a. boosted its stake in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after buying an additional 134 shares during the last quarter. Institutional investors own 99.06% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on LNTH. StockNews.com upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday. JMP Securities restated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. B. Riley reduced their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. Finally, Truist Financial reduced their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $132.67.

Lantheus Price Performance

Shares of Lantheus stock traded up $1.42 during trading on Friday, hitting $81.86. The company's stock had a trading volume of 1,561,278 shares, compared to its average volume of 968,940. Lantheus Holdings, Inc. has a 52 week low of $75.00 and a 52 week high of $126.89. The stock has a market cap of $5.61 billion, a price-to-earnings ratio of 13.62 and a beta of 0.23. The stock has a 50-day moving average price of $99.57 and a two-hundred day moving average price of $94.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The firm had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business's revenue was up .8% compared to the same quarter last year. During the same period last year, the company posted $1.69 EPS. On average, equities analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This represents a 10.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 63,109 shares of company stock valued at $6,016,046. 2.00% of the stock is currently owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.